Dirk Strumberg

Summary

Affiliation: Marienhospital Herne
Country: Germany

Publications

  1. ncbi Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study
    D Strumberg
    Department of Hematology and Medical Oncology, University of Bochum, Marienhospital Herne, Hölkeskampring 40, D 44625 Herne, Germany
    Br J Cancer 106:1722-7. 2012
  2. ncbi Regorafenib for cancer
    Dirk Strumberg
    University of Bochum, Marienhospital Herne, Department of Hematology and Medical Oncology, 40, 44625 Herne, Germany
    Expert Opin Investig Drugs 21:879-89. 2012
  3. ncbi Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer
    Dirk Strumberg
    Department of Hematology and Medical Oncology, University of Bochum, Marienhospital Herne, Hölkeskampring 40, 44625, Herne, Germany
    Invest New Drugs 30:1138-43. 2012
  4. ncbi Phase I study of telatinib (BAY 57-9352): analysis of safety, pharmacokinetics, tumor efficacy, and biomarkers in patients with colorectal cancer
    Klaus Mross
    Tumor Biology Center at the Albert Ludwigs University Freiburg, Germany
    Vasc Cell 3:16. 2011
  5. ncbi Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?
    D Strumberg
    Department of Internal Medicine and Medical Oncology, West German Cancer Center, University Medical School of Essen, Essen, Germany
    Eur J Cancer 42:548-56. 2006
  6. ncbi Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment
    Dirk Strumberg
    Department of Hematology and Medical Oncology, Marienhospital Herne, University of Bochum, Herne, Germany
    Drugs Today (Barc) 41:773-84. 2005
  7. ncbi Phase I dose escalation study of telatinib (BAY 57-9352) in patients with advanced solid tumours
    D Strumberg
    Department of Haematology and Medical Oncology, University of Bochum Marien Hospital, Herne, Herne, Germany
    Br J Cancer 99:1579-85. 2008
  8. ncbi Sorafenib for the treatment of renal cancer
    Dirk Strumberg
    University of Bochum Hematology and Oncology, Marienhospital Herne, Hölkeskampring 40, 44625 Herne, Germany
    Expert Opin Pharmacother 13:407-19. 2012
  9. ncbi Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors
    Dirk Strumberg
    Department of Hematology and Medical Oncology, Marienhospital Herne, University Medical School of Bochum, Herne, Germany
    Oncologist 12:426-37. 2007
  10. ncbi Results of a phase I trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer
    Petra Kupsch
    West German Cancer Center, University of Essen, Germany
    Clin Colorectal Cancer 5:188-96. 2005

Collaborators

Detail Information

Publications34

  1. ncbi Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study
    D Strumberg
    Department of Hematology and Medical Oncology, University of Bochum, Marienhospital Herne, Hölkeskampring 40, D 44625 Herne, Germany
    Br J Cancer 106:1722-7. 2012
    ..In a phase I dose-escalation study, regorafenib demonstrated tolerability and antitumour activity in solid tumour patients. The study was expanded to focus on patients with metastatic colorectal cancer (CRC)...
  2. ncbi Regorafenib for cancer
    Dirk Strumberg
    University of Bochum, Marienhospital Herne, Department of Hematology and Medical Oncology, 40, 44625 Herne, Germany
    Expert Opin Investig Drugs 21:879-89. 2012
    ..Moreover, regorafenib has recently been granted Orphan Drug Status for GIST tumors and 'fast track' status for both GIST and CRC by the FDA...
  3. ncbi Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer
    Dirk Strumberg
    Department of Hematology and Medical Oncology, University of Bochum, Marienhospital Herne, Hölkeskampring 40, 44625, Herne, Germany
    Invest New Drugs 30:1138-43. 2012
    ..This study was aimed at evaluating the safety and efficacy of nimotuzumab monotherapy in patients (pts) with locally advanced or metastatic pancreatic cancer...
  4. ncbi Phase I study of telatinib (BAY 57-9352): analysis of safety, pharmacokinetics, tumor efficacy, and biomarkers in patients with colorectal cancer
    Klaus Mross
    Tumor Biology Center at the Albert Ludwigs University Freiburg, Germany
    Vasc Cell 3:16. 2011
    ..abstract:..
  5. ncbi Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?
    D Strumberg
    Department of Internal Medicine and Medical Oncology, West German Cancer Center, University Medical School of Essen, Essen, Germany
    Eur J Cancer 42:548-56. 2006
    ..05). Sorafenib was well tolerated at the RDP, and induced sustained disease stabilization, particularly in patients with skin toxicity/diarrhoea...
  6. ncbi Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment
    Dirk Strumberg
    Department of Hematology and Medical Oncology, Marienhospital Herne, University of Bochum, Herne, Germany
    Drugs Today (Barc) 41:773-84. 2005
    ..Approval of sorafenib by the U.S. Food and Drug Administration for this indication is pending. A first-line phase III study in RCC as well as phase III studies in hepatocellular carcinoma and metastatic melanoma have been initiated...
  7. ncbi Phase I dose escalation study of telatinib (BAY 57-9352) in patients with advanced solid tumours
    D Strumberg
    Department of Haematology and Medical Oncology, University of Bochum Marien Hospital, Herne, Herne, Germany
    Br J Cancer 99:1579-85. 2008
    ..Telatinib is safe and well tolerated up to a dose of 1500 mg BID continuous dosing. Based on pharmacokinetic and pharmacodynamic criteria, 900 mg telatinib BID continuously administered was selected as the recommended phase II dose...
  8. ncbi Sorafenib for the treatment of renal cancer
    Dirk Strumberg
    University of Bochum Hematology and Oncology, Marienhospital Herne, Hölkeskampring 40, 44625 Herne, Germany
    Expert Opin Pharmacother 13:407-19. 2012
    ..In addition, we need predictive biomarkers to preselect the patients with the best chances of benefiting from sorafenib, in the context of personalized medicine...
  9. ncbi Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors
    Dirk Strumberg
    Department of Hematology and Medical Oncology, Marienhospital Herne, University Medical School of Bochum, Herne, Germany
    Oncologist 12:426-37. 2007
    ..Based on these findings, continuous daily 400 mg bid sorafenib was chosen as the optimal regimen for phase II/III studies. Trials are ongoing in renal cell carcinoma, hepatocellular carcinoma, melanoma, and non-small cell lung cancer...
  10. ncbi Results of a phase I trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer
    Petra Kupsch
    West German Cancer Center, University of Essen, Germany
    Clin Colorectal Cancer 5:188-96. 2005
    ..This dose is recommended for phase II studies...
  11. ncbi Results of a phase II trial of S-1 as first-line treatment of metastatic pancreatic cancer (CESAR-study group)
    Beate Schultheis
    Department of Haematology and Medical Oncology, University of Bochum Marienhospital Herne, Herne, Germany
    Invest New Drugs 30:1184-92. 2012
    ..This study evaluated the antitumor effect and safety of S-1 in Caucasian patients with metastatic PC...
  12. ncbi Raf kinase inhibitors in oncology
    Dirk Strumberg
    Department of Internal Medicine and Medical Oncology, West German Cancer Center, University of Essen, Germany
    Onkologie 28:101-7. 2005
    ..Clinically most advanced is the Raf inhibitor BAY 43-9006, which recently entered phase III clinical testing. This review addresses the rationale for targeting Raf kinase and the current status of various pharmacological approaches...
  13. ncbi Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors
    Dirk Strumberg
    Department of Internal Medicine and Medical Oncology, West German Cancer Center, University Medical School of Essen, Germany
    J Clin Oncol 23:965-72. 2005
    ..This study established the safety and pharmacokinetics of BAY 43-9006 in 69 patients with advanced refractory solid tumors...
  14. ncbi The Raf kinase inhibitor BAY 43-9006 reduces cellular uptake of platinum compounds and cytotoxicity in human colorectal carcinoma cell lines
    Martina Heim
    Department of Internal Medicine and Medical Oncology, West German Cancer Centre, University Medical School of Essen, Essen, Germany
    Anticancer Drugs 16:129-36. 2005
    ..Our results indicate that the Raf kinase inhibitor BAY 43-9006 might also directly or indirectly interact with platinum transporter proteins in vitro...
  15. ncbi Phase I open-label study of cediranib, an oral inhibitor of VEGF signalling, in combination with the oral Src inhibitor saracatinib in patients with advanced solid tumours
    Tanja Trarbach
    Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University Duisbug Essen Essen, Hufelandstr 55, 45122, Essen, Germany
    Invest New Drugs 30:1962-71. 2012
    ..The primary endpoint was safety/tolerability. Secondary assessments included pharmacokinetics and preliminary efficacy...
  16. ncbi Antiretroviral activity of two polyisoprenylated acylphloroglucinols, 7-epi-nemorosone and plukenetione A, isolated from Caribbean propolis
    D Diaz-Carballo
    Institute for Molecular Oncology and Experimental Therapeutics, Marienhospital Herne, Ruhr University of Bochum, Herne, Germany
    Int J Clin Pharmacol Ther 48:670-7. 2010
    ..Plukenetione A is for the first time shown to have antiretroviral activity...
  17. ncbi Effect of food and a proton pump inhibitor on the pharmacokinetics of S-1 following oral administration of S-1 in patients with advanced solid tumors
    Max E Scheulen
    West German Cancer Center, University of Essen, Essen, Germany
    Cancer Chemother Pharmacol 69:753-61. 2012
    ..This study investigated the food effects on the pharmacokinetics (PK) of Oxo, other components of S-1, and their metabolites at different gastric pH adjusted by proton pump inhibitor (PPI)...
  18. ncbi Results of phase I pharmacokinetic and pharmacodynamic studies of the Raf kinase inhibitor BAY 43-9006 in patients with solid tumors
    D Strumberg
    University of Essen, West German Cancer Center, Essen, Germany
    Int J Clin Pharmacol Ther 40:580-1. 2002
  19. ncbi A phase I clinical and pharmacokinetic study of the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with doxorubicin in patients with solid tumors
    H Richly
    University of Essen, West German Cancer Center, Essen, Germany
    Int J Clin Pharmacol Ther 41:620-1. 2003
  20. ncbi Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors
    H Richly
    West German Cancer Center, University of Essen, Essen, Germany
    Ann Oncol 17:866-73. 2006
    ..These promising efficacy results justify further clinical investigation...
  21. ncbi Correlation of ERK-phosphorylation and toxicities in patients treated with the Raf kinase inhibitor BAY 43-9006
    R A Hilger
    Department of Internal Medicine (Cancer Research, University of Essen Medical School, West German Cancer Center, Essen, Germany
    Int J Clin Pharmacol Ther 42:648-9. 2004
  22. ncbi 7-epi-nemorosone from Clusia rosea induces apoptosis, androgen receptor down-regulation and dysregulation of PSA levels in LNCaP prostate carcinoma cells
    David Díaz-Carballo
    Ruhr University of Bochum, Marienhospital Herne, Herne, Germany
    Phytomedicine 19:1298-306. 2012
    ..Here, we demonstrate for the first time that 7-epi-nemorosone exerts cytotoxicity in an androgen-dependent prostate carcinoma entity by targeting the MEK1/2 signal transducer...
  23. ncbi The Ras-Raf-MEK-ERK pathway in the treatment of cancer
    R A Hilger
    Department of Internal Medicine and Medical Oncology, West German Cancer Center, University Medical School of Essen, Germany
    Onkologie 25:511-8. 2002
    ..A number of drugs inhibiting Ras, Raf or MEK are currently under clinical investigation. This review addresses the rationale for targeting the MAP kinase pathway and the current status of various pharmacological approaches...
  24. ncbi ERK1/2 phosphorylation: a biomarker analysis within a phase I study with the new Raf kinase inhibitor BAY43-9006
    R A Hilger
    , Innere Klinik und Poliklinik (Tumorforschung, Abteilung Pharmakologie Antineoplasticher Substanzen, Essen, Germany
    Int J Clin Pharmacol Ther 40:567-8. 2002
  25. ncbi Antitumor effect and potentiation or reduction in cytotoxic drug activity in human colon carcinoma cells by the Raf kinase inhibitor (RKI) BAY 43-9006
    M Heim
    University of Essen, West German Cancer Center, Essen, Germany
    Int J Clin Pharmacol Ther 41:616-7. 2003
  26. ncbi Combined detection of Her2/neu gene amplification and protein overexpression in effusions from patients with breast and ovarian cancer
    Birgitta Schlüter
    Marienhospital Herne, Medizinische Klinik III Hämatologie und Onkologie, Klinikum der Ruhr Universitat Bochum, Hölkeskampring 40, 44625, Herne, Germany
    J Cancer Res Clin Oncol 136:1389-400. 2010
    ....
  27. ncbi Circadian rhythm in the regulation of the MAP kinase pathway--pitfall in the determination of surrogate parameters?
    R A Hilger
    Department of Internal Medicine Cancer Research, University of Essen Medical School, West German Cancer Center, Essen, Germany
    Int J Clin Pharmacol Ther 41:614-5. 2003
  28. ncbi Results of a phase I trial of BAY 43-9006 in combination with doxorubicin in patients with primary hepatic cancer
    H Richly
    West German Cancer Center, University of Essen, Germany
    Int J Clin Pharmacol Ther 42:650-1. 2004
  29. ncbi [Metastases with CUP syndrome]
    S Seeber
    Innere Klinik und Poliklinik (Tumorforschung, Westdeutsches Tumorzentrum, , Essen, Germany
    Urologe A 45:614-9. 2006
    ..For all other patients, toxic therapies are recommended only for patients with good functional status, for palliation of symptoms when they develop, and for continuous support of the quality of life...
  30. ncbi Pharmacokinetics (PK) of a liposomal encapsulated fraction containing doxorubicin and of doxorubicin released from the liposomal capsule after intravenous infusion of Caelyx/Doxil
    R A Hilger
    Department of Internal Medicine (Cancer Research, University of Essen Medical School, West German Cancer Center, Essen, Germany
    Int J Clin Pharmacol Ther 43:588-9. 2005
  31. ncbi [Carcinoma of unknown primary site (CUP syndrome)]
    A Sendler
    Chirurgische Klinik, Marienhospital Herne, Klinikum der Ruhr Universitat Bochum, Hölkeskampring 40, Herne, Germany
    Chirurg 79:689-95; quiz 696. 2008
    ..Toxic therapies are recommended only for palliation of symptoms and maintaining quality of life support in patients with good functional status. Patients should be encouraged to participate in clinical trials for novel therapies...
  32. ncbi Efficacy of sunitinib and sorafenib in non-clear cell renal cell carcinoma: results from expanded access studies
    Dirk Strumberg
    J Clin Oncol 26:3469-71; author reply 2471. 2008
  33. ncbi Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma
    Jaffer A Ajani
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 24:663-7. 2006
    ..We conducted a phase II multi-institutional trial, in the West, in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma to evaluate activity and safety of this combination...
  34. ncbi Extended safety and efficacy data on S-1 plus cisplatin in patients with untreated, advanced gastric carcinoma in a multicenter phase II study
    Heinz Joseph Lenz
    Department of Medical Oncology, University of Southern California, Los Angeles, California, USA
    Cancer 109:33-40. 2007
    ....